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National Typhoid and Paratyphoid Fever 
Surveillance Annual Summary, 2013 
An overview of the National Typhoid and Paratyphoid Fever Surveillance (NTPFS) system is available at  
http://www.cdc.gov/ncezid/dfwed/PDFs/typhi_surveillance_overview_508c.pdf
National Typhoid and Paratyphoid Fever Surveillance Data
Jurisdictions1 reporting at least one typhoid or paratyphoid fever2 case to the NTPFS during 2013 are shown in 
Figures 1 and 2.
 ● 37 jurisdictions reported 284 typhoid fever cases (Figure 1) 
 ● 24 jurisdictions reported 73 paratyphoid fever cases (Figure 2)
Figure 1. Jurisdictions reporting at least one typhoid fever case to National Typhoid and 
Paratyphoid Fever Surveillance, 2013 (n = 284) 
1 Includes all 50 states and District of Columbia
2 Paratyphoid fever is caused by Salmonella serotypes Paratyphi A, Paratyphi B, and Paratyphi C. Two distinct 
pathotypes of Paratyphi B are recognized; one is associated with paratyphoid fever and the other is associated with 
uncomplicated gastroenteritis. The two pathotypes have distinct virulence characteristics, and are differentiated 
based on the ability to ferment tartrate. The paratyphoidal pathotype is unable to ferment tartrate and is 
designated serotype Paratyphi B; the nonparatyphoidal pathotype ferments tartrate and is designated serotype 
Paratyphi B var. L (+) tartrate+. Only those isolates laboratory confirmed as not able to ferment tartrate are 
included in the annual NTPFS summary. For many Paratyphi B reports submitted to CDC, this information is not 
available; these reports are therefore excluded from the NTPFS summary.
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Figure 2. Jurisdictions reporting at least one paratyphoid fever case to National Typhoid 
and Paratyphoid Fever Surveillance, 2013 (n = 73; all were Paratyphi A) 
Demographic and clinical characteristics of patients with typhoid fever and paratyphoid fever are shown in Tables 
1 and 2.
 ● The median age of patients with typhoid fever was 27 years
 ● The median age of patients with paratyphoid fever was 31 years
 ● Zero patients with typhoid fever died
 ● Zero patients with paratyphoid fever died
Table 1. Demographic and clinical characteristics of patients with typhoid fever reported to 
National Typhoid and Paratyphoid Fever Surveillance, 2013 (n = 284) 
Characteristic (total number) Count Percent
Median age in years (range) 27 (1 – 93) ---
Female (n = 281) 135 48
US Citizen (n = 105) 72 69
Foreign travel (n = 279)1 227 81
Vaccinated 2 (n = 171) 8 5
Site of isolation (n = 278)
   Blood 236 85
   Stool 34 12
   Gallbladder 6 2
   Other 2 1
Hospitalized (n = 280) 213 76
Died (n = 249) 0 0
1 Travel destinations are shown in Table 3
2 Received typhoid vaccination within 5 years before onset of illness; of the 8 cases 
in vaccinated persons, 1 received only the oral, live attenuated vaccine (Ty21a), 1 
received the Vi capsular polysaccharide vaccine (ViCPS) and the oral, live attenuated 
vaccine, and the vaccine type was not reported for the other 6. 
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Table 2. Demographic and clinical characteristics of patients with paratyphoid fever reported to 
National Typhoid and Paratyphoid Fever Surveillance, 2013 (n = 73; all were Paratyphi A) 
Characteristic (total number) Count Percent
Median age in years (range) 31, (2 - 59) ---
Female (n = 72) 39 54
US Citizen (n = 21) 17 81
Foreign travel (n = 71)1 64 90
Site of isolation (n = 73) 61 11
   Blood 61 84
   Stool 11 15
   Gallbladder 1 1
Hospitalized (n = 72) 45 62
Died (n = 70) 0 0
1 Travel destinations are shown in Table 3.
● Two-hundred twenty-seven (80%) patients with typhoid fever reported traveling or living outside the United States in the 30
days before illness onset, 52 (18%) reported no travel, and travel status was not reported for 5 (2%) patients.
● Sixty-four (88%) patients with paratyphoid fever reported traveling or living outside the United States in the 30 days before
illness onset, 7 (10%) reported no travel, and travel status was not reported for 2 (2%) patients.
 ● Of those patients reporting travel, 207 (74%) patients with typhoid fever and 59 (83%) patients with paratyphoid fever
reported travel to a single destination (Table 3).
 ● Visiting friends or relatives was the most common reason for travel for patients with typhoid fever (51%) and paratyphoid
fever (44%)
Table 3.  Travel destinations for patients who reported a single destination country, National 
Typhoid and Paratyphoid Fever Surveillance, 2013 
Travel Destination Typhoid (n = 207) Paratyphoid (n = 59)
no. (%) no. (%)
India 117 (57) 34 (58)
Bangladesh 18 (9) 4 (7)
Pakistan 11 (5) 6 (10)
Guatemala 9 (4) ---
El Salvador 7 (3) ---
Cambodia --- 11 (19)
Indonesia --- 3 (5)
Other 45 (22)1 1 (2)2
1 Patients reported travel to Haiti (6), Mexico (5), Nepal (5), Samoa (5), Philippines (5), Indonesia (3), 
Cambodia (2), Chad (2), Dominican Republic (2), Nigeria (2), Tanzania (2), The Bahamas (1), Democratic 
Republic of the Congo (1), Peru (1), Rwanda (1), and Ukraine (1)
2 Patient reported travel to Nepal
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Surveillance performance measures
Reporting statistics and goals for National Typhoid and Paratyphoid Fever Surveillance (below) were proposed at the 2012 Council 
of State and Territorial Epidemiologists (CSTE) Annual Meeting (2).
State-specific summaries were sent to state epidemiologists in November 2015. Health department personnel may request their 
state’s reporting statistics by emailing edebresponse@cdc.gov. 
Table 4. National typhoid fever reporting statistics by year, National Typhoid and Paratyphoid Fever Surveillance (NTPFS), 
2000 – 20131 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Number of jurisdictions reporting 
typhoid fever cases to NTPFS2
50 50 50 50 50 50 50 50 50 50 50 49 50 51
Number of case reports received 
by NTPFS
258 232 201 275 248 204 324 414 437 343 434 363 298 284
Number of cases reported to 
NNDSS
377 368 321 356 322 324 354 435 449 398 472 394 358 350
NTPFS case reports as a 
percentage of NNDSS reports3
68% 63% 63% 77% 77% 63% 92% 95% 97% 86% 92% 92% 83% 81%
Reporting timeliness 
Proportion of reports submitted 
within 30 days after specimen 
obtained4
61% 52% 64% 64% 70% 68% 47% 48% 56% 57% 48% 57% 33% 49%
Reporting completeness 
Proportion of reports with 
"complete" demographic 
information5
84% 92% 91% 87% 93% 85% 85% 89% 80% 76% 84% 90% 88% 86%
Proportion of reports with 
"complete" epidemiologic 
information6
86% 91% 89% 89% 78% 90% 71% 72% 80% 75% 85% 70% 68% 47%
Proportion of reports with 
"complete" travel destination 
information7
98% 96% 99% 100% 98% 97% 98% 99% 98% 99% 99% 99% 100% 99%
Proportion of reports with 
"complete" vaccination 
information8
84% 79% 83% 73% 73% 75% 69% 71% 65% 63% 70% 53% 64% 60%
Proportion of reports with 
"complete" vaccine type 
information9
80% 20% 75% 33% 43% 50% 64% 39% 32% 57% 46% 44% 50% 25%
1 The national typhoid fever and paratyphoid fever surveillance data are dynamic; data from previous years may change as surveillance case reports are added or corrected
2 Includes all states and District of Columbia
3 Is not calculable when no cases are reported to NNDSS; can be greater than 100% if more cases are reported to NTPFS than to NNDSS
4 Is not calculable when no NTPFS reports are received or when dates are not submitted
5 For purposes of this report, “complete” demographic information is defined as information for all of the following: age or date of birth, sex, hospitalization status, and case 
outcome
6 For purposes of this report, “complete” epidemiologic information is defined as information for all of the following: international travel, whether the patient was a food 
handler, whether part of an outbreak, and citizenship
7 For purposes of this report, “complete” travel destination information is defined as report of at least one travel destination if patient reported travel outside of the US in the 
30 days before illness onset
8 For purposes of this report, “complete” vaccination information is defined as a response of “Yes”, “No”, or “Don’t know” regarding receipt of typhoid vaccination primary 
series or booster within 5 years before illness onset
9 For the purposes of this report, “complete” vaccine type information was calculated for patients whose reports specified receipt of typhoid fever vaccination within 5 years 
before illness onset; a response of “unknown” was considered missing for this variable 
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Table 5. National paratyphoid fever reporting statistics by year, National Typhoid and Paratyphoid Fever Surveillance (NTPFS), 
2007 – 20131 
2007 2008 2009 2010 2011 2012 2013
Number of jurisdictions reporting paratyphoid fever cases to NTPFS2 50 50 50 50 49 50 51
Number of case reports received 4 86 77 116 111 81 73
Reporting timeliness
Proportion of reports submitted within 30 days after specimen obtained3 25% 61% 30% 35% 43% 41% 39%
Reporting completeness
Proportion of reports with "complete" demographic information4 100% 81% 77% 89% 89% 84% 95%
Proportion of reports with "complete" epidemiologic information5 100% 80% 87% 89% 67% 67% 49%
Proportion of reports with "complete" travel destination information6 100% 100% 100% 100% 100% 100% 100%
Proportion of reports with "complete" vaccination information7 50% 49% 52% 47% 39% 46% 32%
Proportion of reports with "complete" vaccine type information8 100% 80% 83% 79% 67% 88%
1 The national typhoid fever and paratyphoid fever surveillance data are dynamic; data from previous years may change as surveillance case reports are added or corrected
2 Includes all states and District of Columbia
3 Is not calculable when no NTPFS reports are received or when dates are not submitted
4 For purposes of this report, “complete” demographic information is defined as information for all of the following: age or date of birth, sex, hospitalization status, and case 
outcome
5 For purposes of this report, “complete” epidemiologic information is defined as information for all of the following: international travel, whether the patient was a food 
handler, whether part of an outbreak, and citizenship
6 For purposes of this report, “complete” travel destination information is defined as report of at least one travel destination if patient reported travel outside of the US in the 
30 days before illness onset
7 For purposes of this report, “complete” vaccination information is defined as a response of “Yes”, “No”, or “Don’t know” regarding receipt of typhoid vaccination primary 
series or booster within 5 years before illness onset
8 For the purposes of this report, “complete” vaccine type information was calculated for patients whose reports specified receipt of typhoid fever vaccination within 5 years 
before illness onset; a response of “unknown” was considered missing for this variable 
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1 Includes all states and District of Columbia
2 Is not calculable when no cases are reported to NNDSS; can be greater than 100% if more cases are reported to NTPFS than to NNDSS
3 Is not calculable when no NTPFS reports are received or when dates are not submitted
4 For purposes of this report, “complete” demographic information is defined as information for all of the following: age or date of birth, sex, hospitalization status, and case 
outcome
5 For purposes of this report, “complete” epidemiologic information is defined as information for all of the following: international travel, whether the patient was a food 
handler, whether part of an outbreak, and citizenship
6 For purposes of this report, “complete” travel destination information is defined as report of at least one travel destination if patient reported travel outside of the US in the 
30 days before illness onset
7 For purposes of this report, “complete” vaccination information is defined as a response of “Yes”, “No”, or “Don’t know” regarding receipt of typhoid vaccination primary 
series or booster within 5 years before illness onset
8 For the purposes of this report, “complete” vaccine type information was calculated for patients whose reports specified receipt of typhoid fever vaccination within 5 years 
before illness onset; a response of “unknown” was considered missing for this variable
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NNDSS Data
The National Notifiable Disease Surveillance System (NNDSS) collects and compiles reports of nationally notifiable infectious 
diseases, including typhoid fever. Paratyphoid fever is not nationally notifiable. Reports can be found at http://www.cdc.gov/
mmwr/mmwr_nd/index.html 
Antimicrobial Resistance Data
The National Antimicrobial Resistance Monitoring System (NARMS) monitors antimicrobial resistance among enteric bacteria 
(including Salmonella serotypes Typhi and Paratyphi A and C) from humans. In Enterobacteriaceae, resistance to nalidixic acid, an 
elementary quinolone, correlates with decreased susceptibility to ciprofloxacin (MIC = 0.12 µg/mL) and possible fluoroquinolone 
treatment failure. For Salmonella serotypes Typhi and Paratyphi, NARMS defined resistance to traditional first-line antimicrobial 
agents, ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (ACT/S) as multidrug resistant.
The most recently published NARMS annual report is from 2013, available at http://www.cdc.gov/narms/pdf/2013-annual-report-
narms-508c.pdf. The 2013 data showed the following:
For Salmonella serotype Typhi isolates
 ● 67% were resistant to nalidixic acid
 ● 9% were resistant to ciprofloxacin
 ● No isolates were resistant to ceftriaxone
 ● 10% were multidrug resistant
For Salmonella serotype Paratyphi isolates
 ● 81% were resistant to nalidixic acid
 ● 4% were resistant to ciprofloxacin
 ● No isolates were resistant to ceftriaxone
 ● No isolates were multidrug resistant
Outbreak Data
The Foodborne Disease Outbreak Surveillance System (FDOSS) collects reports of foodborne disease outbreaks from local, state, 
tribal, and territorial public health agencies. The most recently published foodborne outbreaks annual report is from 2013, available 
at http://www.cdc.gov/foodsafety/pdfs/foodborne-disease-outbreaks-annual-report-2013-508c.pdf. Data on foodborne disease 
outbreaks are available at wwwn.cdc.gov/foodborneoutbreaks.  
The Waterborne Disease and Outbreak Surveillance System (WBDOSS) collects reports of waterborne disease outbreaks associated 
with drinking water and recreational water from local, state, tribal, and territorial public health agencies. 
Reports are available at http://www.cdc.gov/healthywater/surveillance/surveillance-reports.html.
 ●  In 2013, no typhoid fever outbreaks were reported.
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